S100A9 and esophageal adenocarcinoma: In Barrett’s esophagus (BE), which is a recognized precursor of esophageal adenocarcinoma (EA), miR-196a was recognized as a potential marker of disease progression with SPRR2C and S100A9 as its targets39.